Burrell Terry-Ann

SEC source: 0001601830-24-000097 · wk-form4_1720039177.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,254

F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001601830-24-000073 · wk-form4_1717625544.xml · derivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,193

Underlying: Class A Common Stock · 26,193 shares

Expires 2034-06-03

F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001601830-24-000073 · wk-form4_1717625544.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,411

F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer.

SEC source: 0000950170-24-049854 · ownership.xml · derivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-04-26

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following July 31, 2023 for the subsequent thirty-six months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-049854 · ownership.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,637

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSU vests in three substantially equal annual installments on each of the first three anniversaries of September 30, 2023, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-041437 · ownership.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,137

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001601830-24-000028 · wk-form4_1712180559.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,314

F1 · kind: Shares were issued pursuant to Issuer's Outside Director Compensation Policy.

SEC source: 0000950170-24-040154 · ownership.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,583

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

F2 · balance_after: Includes 283 shares and 683 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023 and March 31, 2024, respectively.

SEC source: 0000950170-24-010480 · ownership.xml · derivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0001209191-23-042305 · doc4.xml · nonDerivative · entry 5

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,847

F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.

F6 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.105 to $12.98 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-23-042305 · doc4.xml · nonDerivative · entry 4

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,122

F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.

F5 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.81 to $14.56 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-23-042305 · doc4.xml · nonDerivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,279

F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.

F4 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.76 to $13.72 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-23-042305 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,474

F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.

F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.60 to $12.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-23-042305 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,545

F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.

F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.60 to $11.59 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-23-038838 · doc4.xml · derivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,224

Underlying: Class A Common Stock · 25,224 shares

Expires 2033-06-16

F2 · shares: The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001209191-23-038838 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,847

F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer.

SEC source: 0000899243-23-010815 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,117

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.79 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-010815 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,303

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · balance_after: Includes 480 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0000899243-23-010132 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,277

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000899243-23-010132 · doc4.xml · derivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-01-31

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-23-013483 · ownership.xml · derivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-01-31

F1 · security: On March 31, 2023, the Reporting Person filed a Form 4 that reported the acquisition of a stock option. The Form 4 inadvertently reported the number of stock options acquired (and the number of shares of common stock underlying such stock options) as 20,000 when, as reported in this amendment, the correct number is 40,000.

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000899243-23-002957 · doc4.xml · derivative · entry 6

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,565

Underlying: Common Stock · 36,152 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 4

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.24, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,429

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002957 · doc4.xml · derivative · entry 5

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,717

Underlying: Common Stock · 1,102 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.48, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002957 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002666 · doc4.xml · derivative · entry 6

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,819

Underlying: Common Stock · 14,810 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 4

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.10, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002666 · doc4.xml · derivative · entry 5

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,629

Underlying: Common Stock · 5,426 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.18, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-002666 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-23-002260 · doc4.xml · derivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,055

Underlying: Common Stock · 39,886 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-23-002260 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,277

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.50, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: Includes 308 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022.

SEC source: 0000899243-23-002260 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,472

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2 · balance_after: Includes 308 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022.

SEC source: 0001209191-23-002059 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,235

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-22-052911 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,414

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-22-041276 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,149

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-22-037631 · doc4.xml · derivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,290

Underlying: Class A Common Stock · 36,290 shares

Expires 2032-06-14

SEC source: 0001209191-22-037631 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,518

F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders.

SEC source: 0001209191-22-023316 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,373

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0000899243-22-013485 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,278

F3 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs.

SEC source: 0000899243-22-013485 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,065

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date.

F2 · balance_after: Includes 256 shares acquired under the Issuer's employee stock purchase plan on March 31, 2022.

SEC source: 0000899243-22-004196 · doc4.xml · derivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with Beam Therapeutics Inc. through each vesting date. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

SEC source: 0001209191-22-002050 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,585

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-059745 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,822

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-045551 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,193

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0000899243-21-027313 · doc4.xml · derivative · entry 4

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,941

Underlying: Common Stock · 30,000 shares

Expires 2029-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F3 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-21-027313 · doc4.xml · nonDerivative · entry 3

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,809

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.